A	C177536	GDC Property Terminology	C104674	Genome-Wide DNA Copy Number	The number of DNA sequence copies found over the entire genome of an individual.	copy_number
A	C177536	GDC Property Terminology	C172272	Electronic File Content Type	The nature of the content stored in an electronic file.	data_type
C	C177536	GDC Property Terminology	C181065	Number of Days Between Index Date and Last Follow Up	The number of days between an index date and the date of last follow up.	days_to_follow_up || days_to_last_follow_up
C	C177536	GDC Property Terminology	C181071	Number of Days Between Index Date and Specimen Collection	The number of days between an index date and the date that a specimen collection procedure occurred.	days_to_collection || days_to_sample_procurement
C	C177536	GDC Property Terminology	C181708	Assay Plate Well Identifier	The identifier assigned to a single well where a specific sample is located in a plate used in an assay.	plate_well || well_number
C	C177536	GDC Property Terminology	C181710	Average Number of Days per Week One Drinks Alcohol	A question regarding the average number of days per week that a subject consumes an alcoholic beverage.	alcohol_days_per_week
A	C177536	GDC Property Terminology	C185074	Personal History Neoplasm Type Question	A request to report the type of neoplastic disease a subject had been diagnosed with in their past.	history_of_tumor_type
A	C177536	GDC Property Terminology	C185077	OCT Embedded Indicator	An indicator that specifies whether a specimen or sample was embedded in optimal cutting temperature (OCT) compound.	oct_embedded
D	C177536	GDC Property Terminology	C42645	Data Type	An indication of the form that a value will have.  Examples include string, integer, and character.	data_type
C	C177536	GDC Property Terminology	C63637	RNA Integrity Number	A numerical assessment of the integrity of RNA based on the entire electrophoretic trace of the RNA sample, including the presence or absence of degradation products.	rin || rna_integrity_number
A	C177537	GDC Value Terminology	C102883	Miscellaneous Neoplasm	A benign or malignant neoplasm which is not further characterized.	Miscellaneous Tumors | disease_type	C2991	disease_type
D	C177537	GDC Value Terminology	C105615	ALK Inhibitor RO5424802	An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ALK inhibitor RO5424802 binds to and inhibits ALK kinase, which leads to a disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	ALK Inhibitor RO5424802 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C12608	Islet of Langerhans	A specialized region of tissue located within the parenchyma of the pancreas that contains a mixed population of distinct endocrine cells, including beta, alpha, pancreatic polypeptide, delta, and epsilon cells, which respectively produce and secrete insulin, glucagon, pancreatic polypeptide, somatostatin, and ghrelin.	Islets of Langerhans | progression_or_recurrence_anatomic_site || Islets of Langerhans | site_of_resection_or_biopsy || Islets of Langerhans | tissue_or_organ_of_origin	C156421 || C156422 || C177570	site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site
C	C177537	GDC Value Terminology	C128030	Evexomostat	A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates.	MetAP2 Inhibitor SDX-7320 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C129693	Gartisertib	An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration,gartisertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.	ATR Kinase Inhibitor VX-803 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C131177	Eragidomide	A modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, eragidomide specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.	Cereblon Modulator CC-90009 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C131289	2-Fluorofucose	An orally bioavailable fluorinated analog of fucose that is a protein fucosylation inhibitor, with potential antineoplastic and immunomodulating activities. Upon administration, 2-fluorofucose (2-FF) mimics fucose and is converted to guanosine diphosphate (GDP)-2FF, which prevents the formation of the fucosylation substrate GDP-fucose, and the incorporation of fucose into glycoproteins by fucosyltransferase. As fucosylation of glycoproteins plays a key role in many biological processes, such as protein function, receptor binding, cell signaling and cellular adhesion, and is essential for tumor progression, blocking fucosylation decreases tumor cell growth. In addition, blocking fucosylation of monoclonal antibodies generates fucose-deficient antibodies that exert enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).	2-Fluorofucose-containing SGN-2FF | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C132258	Ulevostinag	A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.	STING Agonist MK-1454 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C132991	Alrizomadlin	An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.	p53-HDM2 Protein-protein Interaction Inhibitor APG-115 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C135484	Gene Expression Level Analysis	The determination of the level of gene transcription in a biological specimen. (CDISC)	Gene Expression Quantification | data_type	C172272	data_type
D	C177537	GDC Value Terminology	C136424	CSF1R Inhibitor DCC-3014	An orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, CSF1R inhibitor DCC-3014 targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), DCC-3014 inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the tumor microenvironment and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival.	CSF1R Inhibitor DCC-3014 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C137951	Belzupacap Sarotalocan	A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.	Light-activated AU-011 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C147558	Platinum-Resistant Disease	A finding indicating that a cancer is resistant to platinum therapy. For non-gynecologic cancers, the terms "platinum-resistant" and "platinum-refractory" are used interchangeably. For gynecologic cancers, it refers to cancer progression between one and six months of completing the last platinum therapy.	Platinum-resistant | additional_pathology_findings	C158809	additional_pathology_findings
C	C177537	GDC Value Terminology	C151947	Cosibelimab	An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Anti-PD-L1 Monoclonal Antibody CK-301 | therapeutic_agents || Anti-PD-L1 Monoclonal Antibody TG-1501 | therapeutic_agents || Cosibelimab | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C155812	Ozuriftamab Vedotin	An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Upon administration of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of yet not fully elucidated process, only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the cancer cells. ROR2, highly expressed during embryonic development while only minimally expressed on certain normal, healthy cells, is involved in Wnt signal transduction and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation, migration and invasion. High levels of ROR2 expression often correlates with poor prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal conditions.	CAB-ROR2-ADC BA3021 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156076	Autoimmune Atrophic Chronic Gastritis	Chronic atrophic gastritis that is caused by autoimmune destruction of parietal cells in the stomach resulting in hypochlorhydria and decreased production of intrinsic factor.	Autoimmune Atrophic Chronic Gastritis | risk_factor || Autoimmune atrophic chronic gastritis | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C156083	High Grade Dysplasia	A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.	Dysplasia; high grade | additional_pathology_findings || High Grade | dysplasia_degree || High Grade Dysplasia | esophageal_columnar_dysplasia_degree || High Grade Dysplasia | risk_factor	C158809 || C17103 || C177578 || C177641	additional_pathology_findings || risk_factor || dysplasia_degree || esophageal_columnar_dysplasia_degree
C	C177537	GDC Value Terminology	C156084	Low Grade Dysplasia	A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be low.	Dysplasia; low grade | additional_pathology_findings || Low Grade | dysplasia_degree || Low Grade Dysplasia | esophageal_columnar_dysplasia_degree || Low Grade Dysplasia | risk_factor	C158809 || C17103 || C177578 || C177641	additional_pathology_findings || risk_factor || dysplasia_degree || esophageal_columnar_dysplasia_degree
C	C177537	GDC Value Terminology	C156141	Mecbotamab Vedotin	An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB) antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet not fully elucidated process only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon selective binding to AXL-expressing tumor cells and internalization, the cytotoxic agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA). AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases normally expressed on many normal, healthy cells and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis. The CAB antibody allows for efficient and reversible binding to AXL-expressing tumor cells under conditions that are present only in the TME, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing cells under normal conditions.	Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156249	Lisaftoclax	An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.	Bcl-2 Inhibitor APG 2575 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156726	Nofazinlimab	A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Anti-PD-1 Monoclonal Antibody CS1003 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C156774	Golidocitinib	An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.	JAK1 Inhibitor AZD4205 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C157772	Zilovertamab Vedotin	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the ROR1-expressing cancer cells, through an as of yet unknown mechanism of action. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.	Anti-ROR1 ADC VLS-101 | therapeutic_agents	C1909	therapeutic_agents
D	C177537	GDC Value Terminology	C158095	Anti-PD-L1 Monoclonal Antibody TG-1501	A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody TG-1501 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Anti-PD-L1 Monoclonal Antibody TG-1501 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C158504	Linvoseltamab	A human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFvs): one directed again the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the CD3 antigen expressed on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Anti-BCMA/CD3 BiTE Antibody REGN5458 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160195	Inobrodib	An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, inobrodib selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.	p300/CBP Bromodomain Inhibitor CCS1477 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C160788	Bavdegalutamide	An orally available selective androgen receptor (AR)-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Bavdegalutamide is composed of an AR ligand attached to an E3 ligase recognition moiety. Upon oral administration, bavdegalutamide targets and binds to the AR ligand binding domain. E3 ligase is recruited to the AR by the E3 ligase recognition moiety and the AR target protein is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome. This prevents the expression of AR target genes and halts AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. In addition, the degradation of the AR protein releases the ARV-110 is released and can bind to additional AR target proteins. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC).	Androgen Receptor Degrader ARV-110 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C162504	Socazolimab	A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Anti-PD-L1 Monoclonal Antibody ZKAB001 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C164025	Biospecimen Data Supplement	Additional documentation or textual matter added to a study report that contains biospecimen data or related information.	Biospecimen Supplement | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C164028	Clincal Data Supplement	Additional documentation or textual matter added to a study report that contains clinical data or related information.	Clinical Supplement | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C164051	Methylation Beta Value	An estimate for the level of DNA methylation in a set of replicate samples that is calculated as the ratio of average signal intensities for methylated alleles divided by the average signal intensities of methylated alleles (M) plus unmethylated alleles (U) plus an offset factor (a), such that beta (b) equals M/(M+U+a). Beta values must fall between zero and one.	Methylation Beta Value | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C164052	Aligned Sequence Read	The determination of the order of a set of sequenced nucleic acid fragments via alignment to a reference genome.	Aligned Reads | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C164053	Unaligned Sequence Read	A set of sequenced nucleic acid fragments that have not been aligned to each other or to a reference sequence or genome.	Unaligned Reads | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165211	Analysis Metadata	Supporting information that describes the processes used to analyze the experimental data in a study.	Analysis Metadata | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165212	Cell Culture Image	Any image of cells grown or manipulated in a tissue culture.	Cell Culture Image | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165213	Copy Number Estimate	An estimation on the number of copies of a nucleic acid sequence of interest found in a sample using an algorithm that is based on the length and average mass of the sequence of interest and/or involves the normalization of a set of results gathered from similar samples or duplicate runs of a single sample.	Copy Number Estimate | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165214	Run Metadata	Supporting information that describes the nucleic acid sequencing run(s) in a study.	Run Metadata | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165215	Slide Image	Any image of cells or tissue sections on a slide.	Slide Image | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165216	Experiment Metadata	Supporting information that describes the experimental design in a study.	Experiment Metadata | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C165684	Livmoniplimab	A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T-cells (Tregs).  Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.	Anti-GARP Monoclonal Antibody ABBV-151 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C166417	Zegocractin	A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.	Calcium Release-activated Channel Inhibitor CM4620 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C170743	Liposomal Bcl-2 Antisense Oligonucleotide BP1002	A liposomal-based nanoparticle composed of an uncharged P-ethoxy antisense oligodeoxynucleotide (ODN) targeting Bcl-2 mRNA and incorporated in liposomes, with potential antineoplastic activity. Upon administration of liposomal Bcl-2 antisense oligonucleotide BP1002, this agent targets and hybridizes with Bcl-2 mRNA and inhibits the expression of Bcl-2 protein. This may induce tumor cell apoptosis of Bcl2-overexpressing tumor cells and may decrease tumor cell proliferation. Bcl2, a protein involved in regulating programmed cell death, is overexpressed in a wide variety of tumors. It promotes cellular survival and inhibits apoptosis.	Liposomal Bcl-2 Antisense Oligonucleotide  BP1002 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C171138	Bacterial Colonization	The detection of bacteria in or on an anatomic site, medical device or biospecimen.	Colonization, Bacterial | risk_factor || Colonization; bacterial | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C171150	Tumor-Associated Lymphocytosis	A laboratory test result indicating an abnormal increase in the number of lymphocytes in a sample from a subject with a tumor.	Tumor-associated Lymphoid Proliferation | risk_factor || Tumor-associated lymphoid proliferation | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C171154	Tissue Microarray Image	Any image of clinical tissue specimens within a tissue microarray.	Tissue Microarray Image | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C172104	Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10	An orally bioavailable steroidal cortexolone derivative and antagonist of the androgen receptor (AR) and glucocorticoid receptor (GR), with potential antineoplastic activity. Upon oral administration, AR/GR antagonist CB-03-10 specifically binds to AR and GR, inhibits AR and GR activation, and prevents AR- and GR-mediated signaling. This leads to an induction of both extrinsic and intrinsic apoptotic pathways and inhibits cell growth in AR- and GR-overexpressing tumor cells. AR and GR are overexpressed in certain types of cancer cells and are involved in proliferation, survival and chemoresistance of tumor cells.	Androgen Receptor/Glucocorticoid Receptor  Antagonist CB-03-10 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173701	Ginisortamab	A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration,ginisortamab specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.	Anti-gremlin-1 Monoclonal Antibody UCB6114 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C173946	Farletuzumab Ecteribulin	An antibody drug conjugate (ADC) composed of farletuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the folate receptor alpha (FRA; FolRa; FOLR1), and conjugated, via a cathepsin B-cleavable linker, to the microtubule-targeting agent (MTA) eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, with potential antineoplastic activity. Upon administration of farletuzumab ecteribulin, the farletuzumab moiety targets and binds to FRA expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and the induction of tumor cell death in FRA-expressing cells. FRA is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.	Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174042	Imlunestrant	An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.	Selective Estrogen Receptor Degrader LY3484356 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C174419	Fidasimtamab	A recombinant human immunoglobulin G1 (IgG1) bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fidasimtamab simultaneously targets, binds to and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T-cells to HER2-expressing tumor cells. This may inhibit tumor cell proliferation of HER2-overexpressing cells. Inhibition of PD-1-mediated signaling may restore immune function through the activation of T-cells and T-cell-mediated immune responses against the HER2-expressing tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C175876	Vimseltinib	An orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, vimseltinib targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the TME and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival.	CSF1R Inhibitor DCC-3014 | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C176005	Breast Ductal Carcinoma In Situ, Comedo Type	Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.	8501/2 | morphology || Comedocarcinoma, noninfiltrating | primary_diagosis || DCIS, comedo type | primary_diagnosis || Ductal carcinoma in situ, comedo type | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C17649	Other	Different than the one(s) previously specified or mentioned.	Other | additional_pathology_findings || Other | alcohol_type || Other | ann_arbor_b_symptoms_described || Other | biospecimen_anatomic_site || Other | comorbidity || Other | diabetes_treatment_type || Other | dysplasia_type || Other | hpv_positive_type || Other | immunosuppressive_treatment_type || Other | instrument_model || Other | library_selection || Other | method_of_diagnosis || Other | method_of_sample_procurement || Other | molecular_analysis_method || Other | platform || Other | reason_treatment_ended || Other | relationship_type || Other | therapeutic_agents || Other | treatment_anatomic_site || Other | treatment_type || Other | type_of_tobacco_used || Other | variant_type || other | classification_of_tumor || other | race	C157110 || C158809 || C16457 || C166276 || C17049 || C171435 || C173544 || C174459 || C177576 || C177610 || C177629 || C18685 || C1909 || C19770 || C25218 || C4086 || C43283 || C45378 || C45902 || C574 || C70700 || C70729 || C83393 || C99532	hpv_positive_type || additional_pathology_findings || comorbidity || reason_treatment_ended || race || biospecimen_anatomic_site || variant_type || classification_of_tumor || method_of_diagnosis || instrument_model || type_of_tobacco_used || library_selection || therapeutic_agents || molecular_analysis_method || treatment_type || dysplasia_type || ann_arbor_b_symptoms_described || platform || alcohol_type || immunosuppressive_treatment_type || method_of_sample_procurement || treatment_anatomic_site || relationship_type || diabetes_treatment_type
C	C177537	GDC Value Terminology	C17666	Germline Variation	Any mutation that appears in the gametes and which will therefore be transmitted to the progeny with some frequency.	Germline | variant_origin || Simple Germline Variation | data_category	C177604 || C175886	variant_origin || data_category
C	C177537	GDC Value Terminology	C178422	Talc Poudrage	A surgical procedure in which talc is insufflated into the pleural space during thoracoscopy to promote the adhesion of the visceral and parietal layers of the pleura as a treatment for recurring pleural effusion.	Pleurodesis, Talc | treatment_type	C25218	treatment_type
C	C177537	GDC Value Terminology	C179646	Endosalpingiosis	A rare condition characterized by the replacement of the epithelium of an organ which is not related to fallopian tube with ectopic fallopian tube-type ciliated epithelium.	Endosalpingiosis | additional_pathology_findings || Endosalpingiosis | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
A	C177537	GDC Value Terminology	C180523	Clostridium difficile Infection	A bacterial infection caused by Clostridium difficile (Clostridioides difficile), which is a spore-forming, toxin-producing Gram-positive anaerobic bacillus that is transmitted by the fecal-oral route. Infection may cause symptoms ranging from diarrhea to life-threatening inflammation of the colon, and risk factors include use of antibiotic medication, advanced age, and hospital or long-term care facility admission.	Clostridioides difficile (c. diff) | additional_pathology_findings	C158809	additional_pathology_findings
A	C177537	GDC Value Terminology	C181336	Number of Gene Copies	The number of replicas of a particular gene sequence in a genome.	Gene Level Copy Number | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184741	Aggregated Somatic Variation Data	Sequence variation data from non-germline cell or tissue samples that has been aggregated across samples or sequencing runs.	Aggregated Somatic Mutation | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184742	Aligned Reads Index	The full-text index utilized to align nucleotide sequencing read data.	Aligned Reads Index | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184743	Sequence Alignment Workflow	A workflow leveraged to align nucleotide sequencing data.	alignment_workflow | type	C25284	type
A	C177537	GDC Value Terminology	C184744	Copy Number Segment Data	Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number for each region.	Copy Number Segment | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184745	Allele-Specific Copy Number Segment Data	Nucleotide sequence data where repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number of specified alleles in each region.	Allele-Specific Copy Number Segment | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184746	Annotated Somatic Variation Data	Sequence variation data from non-germline cell or tissue samples that has been annotated.	Annotated Somatic Mutation | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184749	BEDPE Format	A text file format used to store genomic paired-end sequencing data that includes coordinates and associated metadata.	BEDPE | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184750	Personal History of Other Central Nervous System Tumor	An individual history of a cancer occurring in the central nervous system, other than those listed.	CNS, other | tumor_code	C177615	tumor_code
A	C177537	GDC Value Terminology	C184751	Personal History of Central Nervous System Rhabdoid Tumor	An individual history of a rhabdoid tumor occurring in the central nervous system.	CNS, rhabdoid tumor | tumor_code	C177615	tumor_code
A	C177537	GDC Value Terminology	C184752	Cohort Level Copy Number Scores	The number of DNA sequence copies found over the entire genome of a cohort.	Cohort Level Copy Number Scores | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184754	Diabetes Is Controlled by Diet	An indication that a subject with diabetes is able to control symptoms by modifying their diet.	Diet Controlled Diabetes | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184755	Differential Gene Expression Level Analysis	The determination and comparison of the levels of gene transcription in a set of at least two biospecimens (often a comparison of expression levels for a diseased- or tumor-derived sample versus a normal sample).	Differential Gene Expression | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184756	Exon RNA Measurement	The determination of the amount of RNA encoded by a specific exon in a biological sample.	Exon Expression Quantification | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184757	Expanded Next Generation Cancer Model	A next generation cancer model that has been expanded using tissue culture or other methods.	Expanded Next Generation Cancer Model | sample_type	C70713	sample_type
A	C177537	GDC Value Terminology	C184758	FoundationOne Report	A document provided by FoundationOne listing the sequence variants, genetic aberrations and tumor biomarker-related findings detected in a solid or liquid tumor sample subjected to their proprietary companion diagnostic (CDx) testing. The report also may contain select clinical data related to the findings.	FoundationOne Report | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184759	Gene Level Copy Number Scores	The number of copies of a specified gene found over an entire genome.	Gene Level Copy Number Scores | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184760	GENIE Report	A document that reports the sequence variants, genetic aberrations and tumor biomarker-related findings detected in a tumor sample and compares the findings to data stored the Genomics Evidence Neoplasia Information Exchange (GENIE) registry.	GENIE Report | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184761	Genome Variation Format	A tab-delimited nine-column file to describe nucleotide sequence variation data. The Genome Variation Format (GVF) is based on the Generic Feature Format Version 3 (GFF3) but the GVF specifies additional text format constraints and allows for additional attributes.	GVF | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184762	IDAT Format	A proprietary, encrypted XML-based, compressed electronic file format from Illumina Inc. for storing genome-wide profiling data. The data contains a summary of the intensity data generated from each probe used during a sequencing run.	IDAT | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184763	Hierarchical Data Format 5	A hierarchical, filesystem-like data format that can store metadata in the form of user-defined, named attributes, which are attached to groups and datasets, and representations of images and tables built up using datasets, groups and attributes.	HDF5 | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184764	IGF-1R Inhibition	Inhibition of insulin-like growth factor 1 receptor activity to prevent proliferation of cancer cells and tumor growth.	IGF-1R Inhibitor | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184765	Personal History of Acute Myeloid Leukemia with Induction Failure	An individual history of acute myeloid leukemia and induction failure.	Induction Failure AML (AML-IF) | tumor_code	C177615	tumor_code
A	C177537	GDC Value Terminology	C184766	Diabetes Is Controlled by Insulin	An indication that a subject with diabetes is able to control symptoms using insulin-based therapies.	Insulin Controlled Diabetes | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184767	Protein Isoform Measurement	The determination of the amount of a specific protein isoform in a biological sample.	Isoform Expression Quantification | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184768	JPEG 2000 Format	A discrete wavelet transform (DWT)-based compression standard electronic file format for storing video images.	JPEG 2000 | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184769	JSON Format	A common open standard file format and data interchange format that uses human-readable text consisting of attribute-value pairs and arrays to store and transmit data.	JSON | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184770	Surface Immunoglobulin Light Chain Kappa	Immunoglobulin kappa proteins expressed on the extracellular surface of the plasma membrane	Kappa, Surface | antigen	C268	antigen
A	C177537	GDC Value Terminology	C184771	Surface Immunoglobulin Light Chain Lambda	Immunoglobulin lambda proteins expressed on the extracellular surface of the plasma membrane.	Lambda, Surface | antigen	C268	antigen
A	C177537	GDC Value Terminology	C184772	Legacy Project	An indication that project information or documentation has been deprecated.	legacy | state	C182054	state
A	C177537	GDC Value Terminology	C184773	Personal History of Liver Toxicity due to Non-Infectious Cause	An indication that a subject a has a history that includes symptoms of liver toxicity that is not due to an infection.	Liver Toxicity (Non-Infectious) | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184774	Masked Intensity Sequencing Data	Sequencing chromatogram data where the low-quality base calls have been masked.	Masked Intensities | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184775	Masked Annotated Somatic Variation Data	Sequence variation data from non-germline cell or tissue samples that has been annotated and where the low-quality base calls have been masked.	Masked Annotated Somatic Mutation | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184776	Masked Copy Number Segment Data	Nucleotide sequence data where the low-quality base calls have been masked and repeated sequences have been segmented into genomic regions to allow the calculation of estimated copy number for each region.	Masked Copy Number Segment | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184777	Masked Somatic Variation Data	Sequence variation data from non-germline cell or tissue samples where the low-quality base calls have been masked.	Masked Somatic Mutation | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184778	MEX Format	A minimal base ASCII file format to facilitate the exchange of data matrices.	MEX | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184779	MicroRNA Measurement	A determination of the amount of microRNA in a biological sample.	miRNA Expression Quantification | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184780	Milliunits per Mole Hemoglobin	A unit of concentration equal to the concentration in milliunits of substance per mole of hemoglobin.	mU/mol Hb | test_units	C67415	test_units
A	C177537	GDC Value Terminology	C184781	Next Generation Cancer Model Expanded Under Non-Conforming Conditions	A next generation cancer model that has been expanded using unconventional culturing methods.	Next Generation Cancer Model Expanded Under Non-Conforming Conditions | sample_type	C70713	sample_type
A	C177537	GDC Value Terminology	C184782	Personal History of Other Cancer Within 5 Years	An individual history of a cancer, other than those listed, within 5 years of the current cancer diagnosis.	Other Cancer Within 5 Years | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184783	Personal History of Other Hematologic Disorder	An individual history of a hematologic disorder, other than those listed.	Other Hematologic Disorders | disease_type	C2991	disease_type
A	C177537	GDC Value Terminology	C184784	Personal History of Other Leukemia	An individual history of leukemia, other than those listed.	Other Leukemias | disease_type	C2991	disease_type
A	C177537	GDC Value Terminology	C184785	Personal History of Other Nonmalignant Systemic Disease	An individual history of a nonmalignant systemic disease, other than those listed.	Other Nonmalignant Systemic Disease | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184786	Personal History of Other Pulmonary Complications	An individual history of a pulmonary complication, other than those listed.	Other Pulmonary Complications | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184787	Biospecimen Collection by Other Surgical Resection Method	A surgical procedure in which cancerous tissue is surgically removed.	Other Surgical Resection Method | method_of_sample_procurement	C70700	method_of_sample_procurement
A	C177537	GDC Value Terminology	C184788	Processed Project	An indication that information or documentation associated with a project has been processed.	processed | state	C182054	state
A	C177537	GDC Value Terminology	C184790	Progestational Intrauterine Device	An intrauterine device impregnated with progestin (synthetic progesterone) that can be inserted into the uterus to prevent conception.	Progestational IUD | therapeutic_agents	C1909	therapeutic_agents
A	C177537	GDC Value Terminology	C184791	Personal History of Renal Failure Requiring Dialysis	An indication that a subject a history of renal failure that required treatment with dialysis.	Renal Failure (Requiring Dialysis) | comorbidity	C16457	comorbidity
A	C177537	GDC Value Terminology	C184793	Raw Intensity Sequencing Data	The four-color nucleotide sequencing chromatogram generated by the sequencing instrument that has not been subjected to any normalization, alignment or other data processing steps.	Raw Intensities | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184794	Raw CpG Island Variation Data	CpG island sequence variation data that has not been subjected to any normalization, alignment or other data processing steps.	Raw CGI Variant | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184795	Raw Somatic Variation Data	Sequence variation data from non-germline cell or tissue samples that has not been subjected to any normalization, alignment or other data processing steps.	Raw Simple Somatic Mutation | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184797	Reverse Phase Protein Array	An antibody-based functional proteomic microarray that can characterize basal protein expression and levels of protein modifications in a series of samples of body fluids or those derived from tissue or cellular lysates.	RPPA | platform || Reverse Phase Protein Array | experimental_strategy	C43622 || C45378	experimental_strategy || platform
A	C177537	GDC Value Terminology	C184798	Serum Mesothelin Measurement	A quantitative measurement of the amount of mesothelin present in a sample of serum.	Serum Mesothelin | laboratory_test	C25294	laboratory_test
A	C177537	GDC Value Terminology	C184799	Single Cell Data	Any data from investigations or experiments performed on samples derived from single cells.	Single Cell Analysis | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184800	Somatic Variation Rate	The frequency of mutations in a sample derived from non-germline cells or tissues.	Somatic Mutation Index | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184801	Somatic Cytogenetic Abnormality Analysis	A technique to detect and/or identify cytogenetic abnormalities in non-germline (somatic) cells.	Somatic Structural Variation | data_category	C175886	data_category
A	C177537	GDC Value Terminology	C184802	Splice Junction Measurement	A determination of the number of transcript splice junctions based on nucleotide sequencing reads extending across the start and/or end of a junction.	Splice Junction Quantification | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C184803	Spontaneous Descent of Undescended Testis	An indication that a subject previously diagnosed with undescended testicle experienced spontaneous resolution without intervention.	Spontaneous Descent | undescended_testis_corrected_method	C182101	undescended_testis_corrected_method
A	C177537	GDC Value Terminology	C184804	SRA-XML Format	An XML-based electronic file format used by the NCBI Sequence Read Archive (SRA) and the European Nucleotide Archive (ENA) to store raw sequencing data from next generation sequencing platforms and any corresponding sequence analysis data and associated metadata for the study, sample and experiment.	SRA-XML | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184805	TARGZ Format	An electronic file containing multiple files archived using the Unix-based tape archive (tar) utility and then compressed with the GNU zip (gzip) utility.	TARGZ | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184806	TBI Format	A tab-delimited file that contains an index for the genome positions in a compressed (zipped) variant call format file.	TBI | data_format	C42761	data_format
A	C177537	GDC Value Terminology	C184807	TARGET Data Coordinating Center Archive	A storage location for historical digital data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project data coordinating center.	TARGET DCC Archive | data_category	C175886	data_category
A	C177537	GDC Value Terminology	C184808	TCGA Data Coordinating Center Archive	A storage location for historical digital data from The Cancer Genome Atlas (TCGA) project data coordinating center.	TCGA DCC Archive | data_category	C175886	data_category
A	C177537	GDC Value Terminology	C184809	Fusion Transcript Sequencing	Transcriptome sequencing where either sequencing reads are aligned to reference genes or genomes and then analyzed by software to identify discordant sequences associated with rearrangements are present or samples are subjected to direct sequencing approaches where either each read pair maps to opposite sides of a chimeric junction or where chimeric transcripts overlapping the fusion junction are identified in the reads.	Transcript Fusion | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C185075	Personal History of Pheochromocytoma or Paraganglioma	An individual history of pheochromocytoma or paraganglioma.	Phenochromocytoma or Paraganglioma | history_of_tumor_type	C185074	history_of_tumor_type
C	C177537	GDC Value Terminology	C26869	Pulmonary Fibrosis	Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).	Pulmonary Fibrosis | comorbidity || Pulmonary interstitial fibrosis | additional_pathology_findings	C158809 || C16457	additional_pathology_findings || comorbidity
C	C177537	GDC Value Terminology	C26882	Sialadenitis	An acute or chronic inflammatory process affecting a salivary gland. Signs and symptoms include pain and tenderness in the affected area.	Sialadenitis | additional_pathology_findings || Sialadenitis | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
A	C177537	GDC Value Terminology	C27789	Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia	A neoplastic clonal expansion of endometrial glands characterized by cytologic changes of the epithelium and the presence of an increased number of endometrial glands. The glands form crowded aggregates with tubular or branching patterns which are cytologically distinct from the background architectural and cytological pattern. It is associated with molecular changes seen in endometrioid endometrial carcinoma, including microsatellite instability, PAX2 inactivation, and PTEN, KRAS, and CTNNB1 gene mutations.	8380/2 | morphology || Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN) | additional_pathology_findings || Atypical hyperplasia/Endometrioid intraepithelial neoplasm | primary_diagnosis	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C28277	Pathology Report	A report that provides a description of the gross and microscopic examination of the specimen and is used to make a diagnosis and to determine treatment. It defines which structures and organs of the body are involved by the tumor, verifies the primary site of the cancer and describes the extent to which it has spread.	Pathology Report | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C28955	Carboxyphthalato-1,2-diaminocyclohexaneplatinum	A second-generation platinum analog with potential antineoplastic activity.  Carboxyphthalato-1,2-diaminocyclohexaneplatinum alkylates DNA at the N-7 position of guanine, thereby producing DNA interstrand crosslinks and DNA strand breaks, and inhibiting DNA replication. (NCI04)	Dacplatinum | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C2917	Carcinoma In Situ	A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.	8010/2 | morphology || Carcinoma in situ | additional_pathology_findings || Carcinoma in situ, NOS | primary_diagnosis || Intraepithelial carcinoma, NOS | primary_diagnosis	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C2950	Cytogenetic Abnormality	An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.	Structural Alteration | data_category || Structural Variation | data_category	C175886	data_category
C	C177537	GDC Value Terminology	C2951	Cirrhosis	A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.	Cirrhosis | additional_pathology_findings || Cirrhosis | risk_factor || Cirrhosis, Unknown Etiology | comorbidity || Liver Cirrhosis (Liver Disease) | comorbidity	C158809 || C16457 || C17103	additional_pathology_findings || comorbidity || risk_factor
C	C177537	GDC Value Terminology	C2978	Cyst	A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.	Cyst(s) | additional_pathology_findings || Cyst(s) | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C3014	Endometriosis	The growth of functional endometrial tissue in anatomic sites outside the uterine body. It most often occurs in the pelvic organs.	Endometriosis | additional_pathology_findings || Endometriosis | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C3137	Inflammation	A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.	Inflammation | additional_pathology_findings || Inflammation | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C3157	Leiomyoma	A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.	8890/0 | morphology || Leiomyoma | additional_pathology_findings || Leiomyoma, NOS | primary_diagnosis	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C3237	Squamous Metaplasia	A morphologic finding indicating the transformation of glandular or transitional epithelial cells to, usually, mature squamous epithelial cells.  Representative examples include squamous metaplasia of bronchial epithelium, cervix, urinary bladder, and prostate gland.	Squamous Metaplasia | risk_factor || Squamous metaplasia | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
A	C177537	GDC Value Terminology	C34584	Endocervical Polyp	A polyp that arises from the endocervix. It is characterized by the presence of endocervical glands and a fibrovascular stroma.	Benign endocervical polyp | additional_pathology_findings	C158809	additional_pathology_findings
C	C177537	GDC Value Terminology	C35541	Hyperkeratosis	Hypertrophy of the outermost layer of the epidermis. It may be caused by physical or chemical irritants, irradiation, infection, or neoplastic processes.	Hyperkeratosis | additional_pathology_findings || Inflammation, Hyperkeratosis | risk_factor	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C35605	Glomerular Vascular Disorder	A disorder that is caused by pathologic changes in the glomerular vasculature.	Glomerular Disease | risk_factor || Glomerular disease | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
A	C177537	GDC Value Terminology	C36015	Asbestos Body		Asbestos bodies | additional_pathology_findings	C158809	additional_pathology_findings
C	C177537	GDC Value Terminology	C36541	Chromosomal Rearrangement	Any change in the structure of one or more chromosomes.	Rearrangement | variant_type || Structural Rearrangement | data_type	C172272 || C173544	data_type || variant_type
C	C177537	GDC Value Terminology	C3712	Squamous Cell Papilloma	A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells without morphologic evidence of malignancy. Most frequently it arises in the oral cavity, nasopharynx, larynx, esophagus, vagina, and vulva.	8052/0 | morphology || Keratotoc papilloma | primary_diagnosis || Squamous cell papilloma, NOS | primary_diagnosis || Squamous papilloma | primary_diagnosis || Squamous papilloma; solitary | additional_pathology_findings	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C4117	Sinonasal Papilloma	A benign neoplasm that arises from the ciliated respiratory mucosa that lines the nasal cavity and paranasal sinuses.  It is classified as inverted papilloma, oncocytic papilloma, and exophytic papilloma. Clinical manifestations include nasal obstruction, epistaxis, and anosmia.	8121/0 | morphology || Schneiderian papilloma, NOS | primary_diagnosis || Sinonasal papilloma | additional_pathology_findings || Sinonasal papilloma, NOS | primary_diagnosis || Sinonasal papilloma, exophytic | primary_diagnosis || Sinonasal papilloma, fungiform | primary_diagnosis	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C48570	Percent Unit	A unit for expressing a number as a fraction of hundred (on the basis of a rate or proportion per hundred).	percent | test_units	C67415	test_units
C	C177537	GDC Value Terminology	C60763	Supplement	Textual matter that is added onto a publication or document, usually at the end; a section added to a book or document to give further information or to correct errors.	Supplementary Files | data_type	C172272	data_type
C	C177537	GDC Value Terminology	C63480	Protein Expression Analysis	Any method of protein detection that can be used to quantify the level of a protein in a sample.	Protein Expression Quantification | data_type	C172272	data_type
A	C177537	GDC Value Terminology	C65104	Square Millimeter	A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.	mm^2 | test_units	C67415	test_units
C	C177537	GDC Value Terminology	C66899	Pleurodesis	A therapeutic surgical procedure in which the pleural space is surgically eliminated by the adherence of the visceral and parietal pleurae.	Pleurodesis | treatment_type || Pleurodesis, NOS | treatment_type	C25218	treatment_type
A	C177537	GDC Value Terminology	C67306	Microgram per Liter	A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumetric mass) defined as the density of a substance which mass equal to one microgram occupies the volume of one liter.	ng/mL | test_units	C67415	test_units
A	C177537	GDC Value Terminology	C6996	Uterine Corpus Adenomyosis	The growth of endometrial tissue inside the muscular wall of the uterine corpus. Clinical manifestations include pain, dysmenorrhea, and menorrhagia.	Adenomyosis | additional_pathology_findings	C158809	additional_pathology_findings
C	C177537	GDC Value Terminology	C74065	Sirolimus Albumin-bound Nanoparticles	The macrolide antibiotic rapamycin bound to nanoparticle albumin with immunosuppressant (see sirolimus) and potential antiangiogenic and antineoplastic activities. Rapamycin binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate a complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. In turn, inhibition of mTOR may result in the inhibition of the phosphatidylinositol 3 (PI-3) kinase/Akt pathway and vascular endothelial cell growth factor (VEGF) secretion, which may result in decreased tumor cell proliferation and tumor angiogenesis. The binding of water-insoluble rapamycin to nanoparticle albumin permits the albumin-mediated endocytosis of rapamycin by tumor cells and endothelial cells.	Nanoparticle Albumin-Bound Rapamycin | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C78204	Regorafenib	The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.	Regorafenib | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C7949	Breast Ductal Carcinoma In Situ, High Grade	Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.	8500/2 | morphology || DIN 3 | primary_diagnosis || Ductal intraepithelial neoplasia 3 | primary_diagnosis	C176985 || C177621	morphology || primary_diagnosis
C	C177537	GDC Value Terminology	C82980	Fungal Colonization	Collection of fungal organisms in an anatomic site or medical device.	Colonization, Fungal | risk_factor || Colonization; fungal | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C8360	Intestinal Metaplasia	A morphologic finding indicating the replacement of epithelial tissue outside the intestines by intestinal-type epithelium.	Intestinal Metaplasia | risk_factor || Intestinal metaplasia | additional_pathology_findings	C158809 || C17103	additional_pathology_findings || risk_factor
C	C177537	GDC Value Terminology	C8366	Intraepithelial Neoplasia	A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).	Epithelial | dysplasia_type || Epithelial Dysplasia | risk_factor || Epithelial dysplasia | additional_pathology_findings	C158809 || C17103 || C4086	additional_pathology_findings || risk_factor || dysplasia_type
C	C177537	GDC Value Terminology	C84879	Iodine I 131 Iopofosine	A radioconjugate composed of iopofosine, a phospholipid ether analog, labeled with the radioactive isotope iodine I 131, with potential antineoplastic activity. Upon administration, iodine I 131 iopofosine selectively accumulates in and retains within tumor cells for a prolonged period of time due to the decreased activity of a phospholipase D (PLD) in tumor cells compared to normal cells, thereby delivering cytotoxic radiation specifically to tumor cells.  PLD is an enzyme found in the cell membrane of normal cells that degrades phospholipids.	Phospholipid Ether-drug Conjugate CLR 131 | therapeutic_agents	C1909	therapeutic_agents
C	C177537	GDC Value Terminology	C9009	Squamous Papillomatosis	A benign squamous neoplasm characterized by a papillary growth pattern, diffusely involving a specific anatomic site.	8060/0 | morphology || Squamous papillomatosis | additional_pathology_findings || Squamous papillomatosis | primary_diagnosis	C158809 || C176985 || C177621	additional_pathology_findings || morphology || primary_diagnosis
A	C177537	GDC Value Terminology	C97927	Gene Variant	A variation in the nucleic acid sequence of a specific gene.	Simple Nucleotide Variation | data_category	C175886	data_category